Parkinson's disease is a long-term (chronic) neurological condition that affects around 12,000 people in Ireland and between 7 and 10 million people worldwide. The disease affects the way the brain co-ordinates body movements like walking and talking, but cognitive abilities are also affected.
There is currently no cure for the disease, but researchers at Trinity have recently published findings of a study which may lead to better treatments for this debilitating illness. The paper has been published in the international Cell Press journal Structure .
Neurons in the part of the brain called 'substantia nigra' (dark matter) produce and release a hormone called dopamine. This hormone acts as a messenger between these cells in the substantia nigra and other parts of the brain which control body movements.
If these specialized neurons become damaged or die, the amount of dopamine in the brain is reduced. This means that the parts of the brain that control movement cease to function normally. The only treatment for Parkinson's disease in the last 20 years has been dopamine replacement therapy. This involves providing a substitute to try to increase the levels of the hormone in the brain. However, the treatment is not completely effective and can wear off over time, and it also has side effects.
The main reason why we lack new treatments is that we don't understand the fundamental mechanism of how neurons become sick and die. No one knows why these particular neurons in the substantia nigra are affected.
In the last few years, the field has completely changed. We have new insight into a gene called LRRK2, which is the most common cause of inherited Parkinson's disease. Although only 10% of Parkinson's cases are inherited, the enzyme that is produced by the LRRK2 gene seems to be overactive in both inherited and 'sporadic' cases.
In other words, afflicted individuals may not have an LRRK2 mutation, but the enzyme 'runs amok' in their neurons anyway. Inhibitors of this enzyme are now in late clinical trials for treatment of Parkinson's disease." Amir Khan, Associate Professor, School of Biochemistry and Immunology at Trinity Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology